Pharmaceutical

Astellas and Sangamo sign capsid deal for neurological diseases

Astellas Pharma and Sangamo have signed a licence agreement for neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.

Dec 21, 2024 - 06:00
Astellas and Sangamo sign capsid deal for neurological diseases
Astellas Pharma and Sangamo have signed a licence agreement for neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.
Read the original article

Tags:

Previous Article

Palleon and Shanghai Henlius Biotech link on autoimmune therapy

Next Article

Magazine: US reproductive laws could limit women’s participation in clinical trials

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Health care mergers facing tougher antitrust scrutiny; tornado hits Pfizer plant and more shortages may result

STAT+: Pharmalittle: Health care mergers facing tougher...

Jul 20, 2023

Genentech review of Tessier-Lavigne paper finds no evidence of fraud — but hints at a different misconduct case

Genentech review of Tessier-Lavigne paper finds no evid...

Apr 7, 2023

STAT+: $100 billion estimate for Ozempic-style weight loss drugs gets wary eye from analysts

STAT+: $100 billion estimate for Ozempic-style weight l...

Dec 5, 2023